_resized.jpg)
(5 September 2024, Kota Damansara, Malaysia) Following the execution of a Letter of Intent in February 2024 between OncoCare Medical Malaysia Sdn. Bhd. (“OncoCare Malaysia”) and Thomson Hospitals Sdn. Bhd. (“THSB”), Templewater is pleased to announce the signing of an exclusive Service Provider Agreement between the two parties for OncoCare Malaysia’s provision of oncology services in Thomson Hospital Kota Damansara (“THKD”).
Under this partnership, OncoCare Malaysia will offer comprehensive, patient-centered treatment options using a tumor site-specific approach tailored to the specialties and clinical interests of the oncologists. This includes innovative oncology clinical trials that provide patients access to the latest advancements in cancer treatment, as well as alternative therapies designed to significantly enhance outcomes and quality of life. This collaborative model aims to improve patient results by leveraging the expertise of various specialists to create a comprehensive and personalized treatment plan.
Dr. Melvin Heng Jun Li, Acting Group Chief Executive Officer of TMC Life Sciences, highlighted that, "Thomson Hospital and OncoCare both prioritize excellence in patient care, innovation, and the continuous pursuit of medical advancements. Our shared values in delivering positive healthcare outcomes make this partnership a powerful alliance that will significantly benefit our patients. We are enthusiastic about the opportunities this collaboration presents and firmly believe it will establish a new standard in oncology care."
Dr. John Low, Chief Executive Officer of OncoCare Malaysia, expressed his enthusiasm for the partnership, emphasizing both parties' commitment to cancer care, "Our partnership is poised to make a significant impact in the fight against cancer, offering hope and a path forward for all those affected by this challenging disease. Helmed by highly trained oncologists and supported by a team dedicated to providing personalized care with a human touch, this affiliation is a testament to our shared commitment to enhancing patient outcomes and advancing cancer treatment while upholding the highest standards of quality and sustainability."
This partnership marks a significant milestone in OncoCare’s regional expansion strategy, building on its established presence in Singapore with a network of 12 specialist oncologists across seven clinics. By partnering with THSB, OncoCare is set to extend its renowned oncology services to a wider patient base in Malaysia, further solidifying its position as a leading cancer care provider in Southeast Asia. Operations are expected to commence in November 2024 and the medical team will be led by Dr. John Low, the Founding Doctor and Chief Executive Officer of OncoCare Malaysia.
THKD, a subsidiary and flagship hospital of TMC Life Sciences Berhad, which is listed on the Main Market of Bursa Malaysia Securities Berhad, has been at the forefront of providing exceptional medical care since 2008. THKD's Oncology and Nuclear Medicine facility features advanced technology to support a wide range of cancer treatments, including systemic therapy, radiotherapy, nuclear medicine, and surgical services. It is home to the first Tri-modality nuclear medicine imaging equipment in the Asia Pacific region, the Mediso AnyScan SPECT/CT/PET imaging system and is equipped with a state-of-the-art linear accelerator (LINAC) that includes a surface image guided system (SIGRT) for treating various cancers. The facility has conducted over 5,500 diagnostic and therapeutic procedures for oncology patients, addressing conditions in areas such as the cervix, breast, lung, rectum, head, neck, and brain.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Templewater
Jason Li
Investor Relations
+852 3187 5000
About Templewater
Founded in 2018, the Templewater Group (“Templewater”) is an alternative asset management firm headquartered in Hong Kong. Templewater provides investment solutions to institutions, entrepreneurs, and family offices across various asset classes including private equity, impact investing, and real estate.
Templewater’s private equity strategy focuses on mid-market control buyout opportunities in the Asia Pacific region, empowering companies and driving innovation across various sectors, with healthcare as one of its primary investment verticals. With a commitment to excellence and sustainable growth, Templewater continues to support its portfolio companies like OncoCare in achieving their vision and expanding their impact.
To learn more about Templewater, please visit www.templewater.com
About OncoCare
Founded in 2007 in Singapore, OncoCare is one of the largest private medical oncology specialist centers providing a one-stop multi-disciplinary services, including diagnosis, cancer treatment, palliative treatment and other professional medical services.
To learn more about OncoCare, please visit www.oncocare.sg
About THSB and THKD
Established in 2008, THSB is the shareholding entity of THKD, the flagship hospital of TMC Life Sciences Berhad with a wide array of specialties. Located in Kota Damansara, THKD is well-linked to Kuala Lumpur via road and the mass rapid transit (MRT) system. With 554 beds, THKD offers comprehensive medical care to the highest international standards through world-class facilities and is fully equipped with innovative technology and excellent customer services.
To learn more about THKD, please visit www.thomsonhospitals.com
